GM-CSF Antibodies

Product description

The present Brief Report about molecules targeting granulocyte-macrophage colony-stimulating factor (GM-CSF) and its receptor or M-CSF or G-CSF and its receptor provides a competitor analysis of these anti-inflammatory antibodies. R&D projects of antibodies targeting GM-CSF/R, M-CSF or G-CSF/R to treat rheumatoid arthritis and other inflammatory diseases such as asthma, COPD, multiple sclerosis and psoriasis are discussed as of January 2008. A total of three different molecules are already in early clinical development and three others to follow within one year. After the establishment of anti-TNF therapies as a medically and economically successful therapy, interest in new targets for treatment of inflammation has shifted to other cytokines such as G/M-CSF/R.

The brief report with 16 pages describes the background of the target and the scientific rationale to develop molecules targeting G/M-CSF/R. The target markets for antibodies to G&M-CSF/R are discussed. The status of clinical and preclinical R&D is described and critically assessed. Individual profiles of the antibodies already in clinical development and to reach clinical development within one year are presented in an executive summary with references. The Brief Report also includes a summary list of the target pipeline with other research projects.

The Target Pipeline Summary presents a list in a tabular format providing information on:

• Drug Codes,
• Target / Mechanism of Action,
• Class of Compound,
• Therapeutic Area,
• Company,
• Indication,
• R&D Stage and additional comments with a hyperlink leading to the source of information.